Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal African Journal of Biochemistry and Molecular Biology Research Kwaghe International Journal of Sciences and Technology
Momina Iftikhar
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Environmental Science Law, Crime, Criminology & Criminal Justice Social Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Phytochemistry and Pharmacology of Oxystelma Esculentum Abdul Wadood Chishti; Muhammad Akram; Urooj Rehman; Fahad Said Khan; Momina Iftikhar; Isaac John Umaru
African Journal of Biochemistry and Molecular Biology Research Vol 2 No 2 (2025): African Journal of Biochemistry and Molecular Biology Research
Publisher : Darul Yasin Al Sys

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58578/ajbmbr.v2i2.5269

Abstract

Several phytochemicals, including glycosides, alkaloids, flavonoids, and saponins, are present in the widespread medicinal herb Oxystelmaesculentum. These physiologically active substances contribute to the herb's pharmacological properties, which include anti-inflammatory, antioxidant, antibacterial, and antidiabetic effects. Research studies have shown that O. esculentum can be used medicinally to treat a variety of ailments, such as fever, pain, respiratory issues, and digestive issues. It may also have neuroprotective properties and help in blood sugar regulation. Even though its therapeutic qualities appear promising, more research must be done to verify its efficacy, safety, and potential for drug development.
Cutting-Edge Discoveries in Cancer Biology and Therapeutic Development Muhammad Akram; Muhammad Abdullah; Momina Iftikhar; Isaac John Umaru
African Journal of Biochemistry and Molecular Biology Research Vol 2 No 2 (2025): African Journal of Biochemistry and Molecular Biology Research
Publisher : Darul Yasin Al Sys

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58578/ajbmbr.v2i2.5306

Abstract

Growth in precision medicine, immunotherapy, genetics, and new therapeutic approaches is driving the rapid progression of cancer science and drug discovery. Greater tailor-made treatments attacking specific genetic abnormalities and immune systems have become an alternative to the one-size-fits-all approach, bringing renewed hope to patients for improved outcomes and fewer adverse effects. The most critical growth impacting the face of cancer research and drug discovery is summarized in this brief. Next-generation sequencing (NGS) and other methods enable complete genomic profiling, which identifies actionable mutations and guides targeted therapy. Stepping away from blanket chemotherapy, scientists can develop more effective and less toxic drugs by understanding the specific mutations that create each patient's cancer. By blocking the brakes of the immune system, these drugs allow T cells to better fight cancer cells. However, research is ongoing to maximize these treatments' efficacy and safety, particularly in the case of solid tumors. Targeting some of the TME components, such as the extracellular matrix or TME-dwelling immune cells, could provide new treatment strategies. Huge amounts of genetic information are being evaluated, potential medicine candidates are being identified, and patient outcomes are being forecast by AI algorithms. In addition, machine learning algorithms are being employed to improve patient stratification, optimize clinical trial design, and personalize treatment regimens using real-time data. Combination Treatments: Combination therapies employing multiple mechanisms of action are gaining increasing popularity as a result of the flexibility and complexity of cancer. For maximizing efficacy and overcoming resistance, researchers are incorporating immunotherapy with targeted therapy, chemotherapy, radiation therapy, and other modalities. The goal is to keep tumor cells from evading treatment by attacking cancer from a variety of angles. These combinations are currently under investigation in clinical trials, which have had promising results, particularly in cancers such as breast, lung, and melanoma.
Understanding Uterine Fibroids: Prevalence, Pathophysiology, and Management Haleema Sadia; Muhammad Akram; Momina Iftikhar; Isaac John Umaru
Kwaghe International Journal of Sciences and Technology Vol 2 No 2 (2025): Kwaghe International Journal of Sciences and Technology
Publisher : Darul Yasin Al Sys

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58578/kijst.v2i2.5458

Abstract

The most common type of benign uterine tumors are uterine fibroids, sometimes referred to as leiomyomas or myomas. Clinical indicators include infertility, obstetric problems, mass symptoms, pelvic tumors, pelvic discomfort, and irregular bleeding. Because of their symptoms, more than 30% of women with leiomyomas might look for therapy. Modern surgical options are based on the operation, although the method of therapy is influenced by the patient's age and desire to avoid "radical" surgery, such as a hysterectomy, or to retain fertility. Uterine fibroids' location, size, and number determine the course of treatment. In the pathogenetic process, fibroids are made up of smooth muscle, fibroblasts, and a significant amount of fibrous extracellular matrix. The shape, location, pathophysiology, and clinical symptoms of fibroids vary significantly. A woman's race can affect her likelihood of developing fibroids; Black women are more likely than White women to get fibroids earlier in life and to have more severe symptoms.
Co-Authors Abdul Wadood Chishti Fahad Said Khan Haleema Sadia Isaac John Umaru Muhammad Abdullah Muhammad Akram Urooj Rehman